<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02098863</url>
  </required_header>
  <id_info>
    <org_study_id>SCCRIP</org_study_id>
    <secondary_id>1U01HL133996</secondary_id>
    <secondary_id>UTHSC-MRC Sub</secondary_id>
    <nct_id>NCT02098863</nct_id>
  </id_info>
  <brief_title>Sickle Cell Clinical Research and Intervention Program</brief_title>
  <official_title>Sickle Cell Clinical Research and Intervention Program</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St. Jude Children's Research Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Methodist Healthcare</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Memphis School of Public Health</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Le Bonheur Children's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Methodist Adult Comprehensive Sickle Cell Center, Memphis, TN</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Alabama at Birmingham</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of North Carolina</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Regional One Health, Diggs-Kraus Sickle Cell Center, Memphis</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>UTHSC-ORNL Center in Biomedical Informatics</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Washington Seattle Cancer Care Alliance</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Medical College of Wisconsin</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Tennessee Health Science Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Children's Hospital of Philadelphia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>St. Jude Children's Research Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Despite the important work of previous sickle cell disease (SCD) cohort studies, there remain
      many understudied areas that require investigation. An important knowledge deficit is the
      slow but progressive process of chronic end-organ dysfunction. The majority of organ
      dysfunction becomes apparent in the young adult years, but comprehensive assessment of adults
      and understanding of predictors of adulthood organ dysfunction are insufficient. Similarly,
      the role of disease-modifying therapies, such as hydroxyurea, in preventing organ dysfunction
      later in life is not clear. Extended follow-up of patients through the transition into
      adulthood is imperative to understand the long-term implications of pediatric sickle cell
      care.

      This observational study will collect data in a systematic fashion at participants' regular
      clinic visits to answer the objectives described below.

      In addition to primary study objectives, SCCRIP participants will be eligible to participate
      in a sub-study, which will investigate genetically determined responses to Hydroxyurea (HU)
      via a pharmacokinetic study (PK). This one time study will involve blood collection at timed
      intervals proceeding a dose of HU. Defining the basis for this inter-individual variability
      will allow the identification of poor HU responders prior to initiation of therapy and the
      seeking of alternative treatments which seek to optimize disease treatment by accounting for
      individual variability in genes, environment, and lifestyle.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The St. Jude Pediatric SCD Program has developed a comprehensive plan of care that spans the
      ages of 0 to 25, and provides the structure for screening and monitoring disease progression
      and complications in infancy, childhood, and young adulthood. From age 0 to 18, SCD patients
      are followed at St. Jude Children's Research Hospital. At age 18, their care is typically
      transferred to either the Methodist Adult Comprehensive Sickle Cell Disease Center in
      Memphis, TN, or the Regional One Health, Diggs-Kraus Sickle Cell Center in Memphis, TN, where
      they are routinely followed from age 18 to 25 years. After age 25, participants will be
      followed and invited to return to St. Jude every 6 years for study related tests until
      participants elect to come off study or until death. Three St. Jude Affiliate locations will
      also be sites of enrollment for this protocol for patients age 0 to 18 years. These include
      St. Jude Affiliate sites located in: Baton Rouge, Louisiana; Peoria, Illinois; and Charlotte,
      North Carolina. Approximately 500 additional participants are expected to be enrolled from
      these affiliate sites. This protocol will collect data on SCD participants from birth to end
      of life.

      The SCD plan of care provides the specific sequence of laboratory and imaging studies that
      are performed according to the patient's age and expected course of illness. The following
      health outcomes are systematically monitored in patients with SCD: hematologic indices,
      pulmonary function, cardiac function, renal function, cognitive function, cerebral
      vasculopathy, vitamin D deficiency and bone health, parvovirus B19 immune status,
      ophthalmologic status, and splenic function. These tests are used to direct the patient's
      clinical management and initiate therapies when necessary.

      In this study, the results of these tests will be collected and entered into the study
      database, providing longitudinal data that will inform health outcomes research regarding SCD
      and how the course is altered by disease-modifying therapy, in addition to facilitating
      future interventional projects.

      Primary Objectives:

        -  To establish a longitudinal clinical cohort of patients with sickle cell disease (SCD)
           to serve as a research resource to facilitate evaluation of health outcomes in SCD from
           pediatric care into adulthood.

        -  To facilitate the collection of biological samples from patients with SCD to be used in
           future studies investigating genetic and epigenetic contributions to disease severity,
           response to treatment, and morbidity and mortality.

      Secondary Objectives:

        -  To determine the incidence, prevalence, and severity of SCD complications and adverse
           health conditions within the SCD cohort during five stages of development and adulthood:
           the newborn period (birth to 6 months), the infant/pre-school stage (ages 6 months to 6
           years), the early school stage (ages 6 to 12 years), the adolescent stage (ages 12 to 18
           years), the years of transition into young adulthood (ages 18 to 25 years), and
           adulthood (ages 26 years and above).

        -  To identify and evaluate risk factors for premature mortality and long-term morbidity in
           patients with SCD, including those related to disease-modifying therapies, end-organ
           damage, genetics, neurocognitive deficits, psychosocial factors, and behavioral causes.

        -  To investigate the long-term effects of hydroxyurea and other therapies on preservation
           of organ function, growth and development, and frequency and severity of disease
           complications, and their long-term medical, neurocognitive, and psychosocial toxicities.

        -  To determine the functional aspects of the Transition to Adult Care Program within a
           clinical research cohort by evaluating disease specific health literacy and readiness in
           relation to healthcare utilization during adult care.

      Other Pre-Specified Objective:

        -  Define the drug-exposure to clinical response relationship of HU therapy in children
           with SCD.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 15, 2014</start_date>
  <completion_date type="Anticipated">December 2044</completion_date>
  <primary_completion_date type="Anticipated">December 2044</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>30 Years</target_duration>
  <primary_outcome>
    <measure>Relationship between treatment plan and health outcomes in participants with sickle cell disease (SCD)</measure>
    <time_frame>Every 2 years from newborn to â‰¤ 30 years of age, and every 6 years after age 30 until end-of-life, up until December 2044</time_frame>
    <description>As described in the Detailed Description, standard of care data will be collected from participants every two years during participants' annual clinic visits until study participation is discontinued or until participants reach 25 years of age, whichever occurs last. This collection of observational data will be entered into a study database and will serve as a research resource to facilitate evaluation of health outcomes in participants with SCD from pediatric care into adulthood.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Relationship between genetic properties of biological samples and health outcomes in participants with sickle cell disease</measure>
    <time_frame>Collected every 6 years from newborn until end-of life, up until December 2044</time_frame>
    <description>A repository of biological samples from participants with sickle cell disease will be established for future retrospective studies investigating genetic and epigenetic contributions to disease severity, response to treatment, and morbidity and mortality.</description>
  </primary_outcome>
  <enrollment type="Anticipated">1550</enrollment>
  <condition>Sickle Cell Disease</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      All participants will be offered the option of having biological specimens collected and
      saved for future research. DNA, plasma, and urine will be collected from participants and
      stored at Tissue Resources at St. Jude Children's Research Hospital. This will facilitate
      future high quality genotype-phenotype studies and other genetic and proteomic studies
      related to variability in disease severity, treatment response, and health outcomes.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Participants with a diagnosis of sickle cell disease of any genotype.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        SCCRIP Inclusion Criteria:

          -  A diagnosis of sickle cell disease of any genotype.

          -  PK Sub-study Inclusion Criteria:

               -  Participants at St. Jude Children's Research Hospital who are consented to the
                  parent protocol (SCCRIP).

               -  Participants currently completing a hydroxyurea (HU) regimen, who have achieved
                  maximum tolerated dose and have maintained that dose for a minimum of 90 days
                  prior to enrollment.

        SCCRIP Exclusion Criteria:

          -  Any medical or social reason, which, in the opinion of the principal investigators
             would make the participation of the subject ill-advised.

          -  PK Sub-study Exclusion Criteria:

               -  Participants unable to complete the blood draws needed for PK sampling.

               -  Inability or unwillingness of research participant or legal
                  guardian/representative to give written informed consent.

               -  Any medical or social reason, which, in the opinion of the principal
                  investigators would make the participation of the subject ill-advised.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jane Hankins, MD, MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. Jude Children's Research Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jane Hankins, MD, MS</last_name>
    <phone>866-278-5833</phone>
    <email>referralinfo@stjude.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Children's Hospital of Illinois at OSF-Saint Francis Medical Center</name>
      <address>
        <city>Peoria</city>
        <state>Illinois</state>
        <zip>61637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kay Saving, MD</last_name>
      <phone>309-624-4945</phone>
    </contact>
    <investigator>
      <last_name>Kay Saving, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Our Lady of the Lake Regional Medical Center</name>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <zip>70808</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeff Deyo, MD, PhD</last_name>
      <phone>225-763-6337</phone>
    </contact>
    <investigator>
      <last_name>Jeff Deyo, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Novant Health Hemby Children's Hospital</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paulette Bryant, MD</last_name>
      <phone>704-384-1900</phone>
    </contact>
    <investigator>
      <last_name>Paulette Bryant, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Regional One Health, Diggs-Kraus Sickle Cell Center</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Patricia Adams-Graves, MD</last_name>
      <phone>901-545-8535</phone>
    </contact>
    <investigator>
      <last_name>Patricia Adams-Graves, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Methodist Adult Comprehensive Sickle Cell Center</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Curtis Owens, MD</last_name>
      <phone>901-516-8182</phone>
    </contact>
    <investigator>
      <last_name>Curtis Owens, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Jude Children's Research Hospital</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jane Hankins, MD, MS</last_name>
      <phone>866-278-5833</phone>
      <email>referralinfo@stjude.org</email>
    </contact>
    <investigator>
      <last_name>Jane Hankins, MD, MS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://stjude.org</url>
    <description>St. Jude Children's Research Hospital</description>
  </link>
  <link>
    <url>http://www.stjude.org/protocols</url>
    <description>Clinical Trials Open at St. Jude</description>
  </link>
  <link>
    <url>https://www.stjude.org/research/clinical-trials/sccrip-hematological-disorder.html</url>
    <description>SCCRIP: Sickle Cell Research and Intervention Program</description>
  </link>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 21, 2014</study_first_submitted>
  <study_first_submitted_qc>March 25, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 28, 2014</study_first_posted>
  <last_update_submitted>January 31, 2018</last_update_submitted>
  <last_update_submitted_qc>January 31, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 1, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Sickle Cell Anemia</keyword>
  <keyword>Sickle Cell Disease</keyword>
  <keyword>Survival</keyword>
  <keyword>Mortality</keyword>
  <keyword>End-Order Dysfunction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia, Sickle Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

